Clinical Trial Update: Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial of vemurafenib in patients with poor performance status and unresectable locally advanced or metastatic melanoma harboring BRAF V600E/K mutation w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Vemurafenib (Zelboraf) (vemurafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2015-04-30